50 related articles for article (PubMed ID: 38580670)
1. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of radiation therapy effects in prostate cancer.
Nilsson S; Norlén BJ; Widmark A
Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
[TBL] [Abstract][Full Text] [Related]
3. The influence of Gleason score ≤ 6 histology on the outcome of high-risk localized prostate cancer after modern radiotherapy.
Yamazaki H; Suzuki G; Masui K; Aibe N; Kimoto T; Yamada K; Okihara K; Hongo F; Okumi M; Shiraishi T; Fujihara A; Yoshida K; Nakamura S; Kato T; Hashimoto Y; Okabe H
Sci Rep; 2024 Apr; 14(1):8011. PubMed ID: 38580670
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
5. Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9-10 clinical localized prostate cancer.
Yamazaki H; Suzuki G; Aibe N; Shimizu D; Kimoto T; Masui K; Yoshida K; Nakamura S; Okabe H
Sci Rep; 2022 Jan; 12(1):268. PubMed ID: 34997125
[TBL] [Abstract][Full Text] [Related]
6. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy.
Hegde JV; Demanes DJ; Veruttipong D; Raince J; Park SJ; Raman SS; Nickols NG; King CR; Kishan AU; Steinberg ML; Kamrava M
Brachytherapy; 2017; 16(6):1106-1112. PubMed ID: 28807747
[TBL] [Abstract][Full Text] [Related]
8. Biochemical outcome after high-dose-rate intensity modulated brachytherapy with external beam radiotherapy: 12 years of experience.
Prada PJ; González H; Fernández J; Jiménez I; Iglesias A; Romo I
BJU Int; 2012 Jun; 109(12):1787-93. PubMed ID: 21981583
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
Nguyen PL; Huang HR; Spratt DE; Davicioni E; Sandler HM; Shipley WU; Efstathiou JA; Simko JP; Pollack A; Dicker AP; Roach M; Rosenthal SA; Zeitzer KL; Mendez LC; Hartford AC; Hall WA; Desai AB; Rabinovitch RA; Peters CA; Rodgers JP; Tran P; Feng FY
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):521-529. PubMed ID: 36596347
[TBL] [Abstract][Full Text] [Related]
10. A national questionnaire survey of Japanese urologists on active surveillance for low- and intermediate-risk prostate cancer.
Kato T; Tohi Y; Honda T; Matsuda I; Osaki Y; Naito H; Matsuoka Y; Okazoe H; Taoka R; Tsunemori H; Ueda N; Sugimoto M
Int J Urol; 2023 Mar; 30(3):289-297. PubMed ID: 36415128
[TBL] [Abstract][Full Text] [Related]
11. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.
Netto GJ; Amin MB; Compérat EM; Gill AJ; Hartmann A; Moch H; Menon S; Raspollini MR; Rubin MA; Srigley JR; Hoon Tan P; Tickoo SK; Tsuzuki T; Turajlic S; Cree I; Berney DM
Eur Urol; 2023 Apr; 83(4):301-303. PubMed ID: 36202687
[TBL] [Abstract][Full Text] [Related]
12. Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of > 60,000 men.
Alam MU; Kumar J; Norez D; Woolfe J; Tanneru K; Jazayeri SB; Bazargani S; Thomas D; Gautam S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Int Urol Nephrol; 2023 Feb; 55(2):295-300. PubMed ID: 36171482
[TBL] [Abstract][Full Text] [Related]
13. Low-grade prostate cancer should still be labelled cancer.
Iczkowski KA; Molina M; Egevad L; Bostwick DG; van Leenders GJLH; La Rosa FG; van der Kwast T; Berney DM; Evans AJ; Wheeler TM; Leite KRM; Samaratunga H; Srigley J; Varma M; Tsuzuki T; Lucia MS; Crawford ED; Harris RG; Stricker P; Lawrentschuk N; Woo HH; Fleshner NE; Shore ND; Yaxley J; Bratt O; Wiklund P; Roberts M; Cheng L; Delahunt B
BJU Int; 2022 Dec; 130(6):741-743. PubMed ID: 36083240
[No Abstract] [Full Text] [Related]
14. Renaming Gleason Score 6 Prostate to Noncancer: A Flawed Idea Scientifically and for Patient Care.
Epstein JI; Kibel AS
J Clin Oncol; 2022 Sep; 40(27):3106-3109. PubMed ID: 35767801
[No Abstract] [Full Text] [Related]
15. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer.
Eggener SE; Berlin A; Vickers AJ; Paner GP; Wolinsky H; Cooperberg MR
J Clin Oncol; 2022 Sep; 40(27):3110-3114. PubMed ID: 35436144
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
